1 / 37

AFP Journal Review January 1, 2009

AFP Journal Review January 1, 2009. Cindi Hurley, MD MBA February 12, 2009. Topics. Principles of Casting & Splinting Mgmt of Blood Sugar in Type 2 Diabetes. Casting & Splinting Review. Assess Need for Immobilization.

veta
Download Presentation

AFP Journal Review January 1, 2009

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. AFP Journal ReviewJanuary 1, 2009 Cindi Hurley, MD MBA February 12, 2009

  2. Topics • Principles of Casting & Splinting • Mgmt of Blood Sugar in Type 2 Diabetes

  3. Casting & Splinting Review

  4. Assess Need for Immobilization • Casts & Splints serve to promote healing, maintain bone alignment, decrease pain, protect the injury and compensate for weakness • Conditions that benefit from immobilization: Fracture Inflammatory conditions Sprains Deep lac repairs across joints Tendon laceration Severe soft tissue injury Reduced joint dislocations

  5. What’s the Difference? • Both start with application of a stockinette & padding • Splinting involves non–circumferential application of a plaster or fiberglass support held in place by an elastic bandage • Casting involves circumferential application of plaster or fiberglass

  6. Splint or Cast? • Must assess the stage & severity of the injury, potential for instability, risk of complications, and patient’s functional requirements • Splints used more often for simple or stable fractures, sprains, tendon injuries & other soft tissue injuries • Casting used for definitive and/or complex fractures

  7. Advantages of Splinting • Faster & Easier to Apply • May be static & prevent motion or dynamic & allow controlled motion • Allows for natural swelling • Easily removed to allow for regular inspection

  8. Disadvantages of Splinting • Allow excessive motion at injury site • Inappropriate for definitive treatment of unstable or potentially unstable fractures such as those requiring reduction, spiral fractures and dislocation fractures

  9. Advantages of Casting • More effective immobilization

  10. Disadvantages of Casting • Takes more time & skill to apply • Higher risk of complications

  11. Complications of Splinting & Casting • Compartment Syndrome • Most serious complication • Increased pressure within a closed space, compromises blood flow & tissue perfusion • If pt experiences severe swelling, worsening pain, numbness or tingling , or dusky appearance  ER • Heat Injury • Pressure Sores and Skin Breakdown • often caused by pressure from a wrinkled, unpadded or underpadded area over a bony prominence

  12. Complications, continued • Infection • Common with open wound • Moist, warm environment is ideal for infection • Ischemia • Dermatitis • Joint Stiffness • Neurological Injury

  13. Guidelines • Inspect the involved extremity and document skin lesions, soft-tissue injuries, and neurovascular status beforehand • Protect the patient’s clothing • Properly position the extremity before, during & after application of materials • Properly pad bony prominences and high-pressure areas

  14. Guidelines, continued • Avoid tension and wrinkles on materials • Use the right temperature of water – the hotter the water the faster the material sets and the greater the risk for heat injuries – use tepid water for plaster and room temp water for fiberglass • Do not dump water used on plaster down the sink – it will clog!

  15. Videos • http://intermed.med.uottawa.ca/procedures/cast/

  16. Follow-Up • Elevate the injured extremity to decrease pain & swelling • Refrain from getting the material wet • Educate pt re: compartment syndrome • Avoid strong opioids so pain is not masked that should prompt a doctor’s visit • Most require initial follow-up within 1 -2 weeks

  17. Management of Blood Glucose in Type 2 Diabetes Mellitus

  18. Statistics on Type 2 Diabetes • 6th cause of death in US • Leading cause of kidney failure • Leading cause of new blindness in adults • More than 20 million Americans have T2DM, however 30% are undiagnosed

  19. We Need to Focus On • Lifestyle Changes • Management of Cardiovascular Risk Factors • Management of Blood Glucose Levels

  20. Lifestyle Modifications • Weight loss goal of 7% • Reduces incidence of T2DM by 58% !!! • Exercise goal of 150 minutes per week • (30 mins/day x 5 days/week) • TLC much more effective than Metformin in reducing blood glucose & HbA1C

  21. Mgmt of Cardiovascular Disease Risk Factors • Interventions to manage blood pressure, cholesterol and microalbuminuria have been shown to decrease mortality • Use ASA if T2DM and • Have existing CAD • Have RFs for CAD • Are over 40 yo

  22. Mgmt of Cardiovascular RF’s • Use Statins if T2DM and - have existing CAD - they are older than 40 with at least one CAD RF • Use ACE or ARBs if T2DM and • Micro- or macroalbuminuria

  23. Management of Blood GlucoseOral Agents • Biguanides • Sulfonylureas • Non-Sulfonylureas • Alpha Glucosidase Inhibitors • Amylin Analogues • Incretin Enhancers • Incretin Mimetics • Thiazolidinediones (TZDs)

  24. Biguanides • Examples: Metformin (Glucophage) • Mechanism: decreases hepatic glucose production and intestinal glucose absorption; and to a lesser extent, increases insulin sensitivity of peripheral cells • SA’s: nausea, diarrhea, flatulence • Caution: RI (d/c if Cr > 1.4), using IV dye • Cost: $20-30/month if generic • Note: 1) only hypoglycemic agent shown to reduce mortality 2) approved for children > 10 yo

  25. Insulin Secretatogues: Sulfonylureas • Examples: Glyburide, Glipizide, Amaryl • Mechanism: incease insulin secretion from the pancreatic islet beta cell by closing K+ channels • SA’s: hypoglycemia, wt gain • Cost: $50/month

  26. Insulin Secretatogues: Non-sulfonylureas • Examples: Starlix, Prandin • Mechanism: stimulates pancreatic islet beta cell insulin release • SA’s: hypoglycemia • Cost: $175/month

  27. Alpha Glucosidase Inhibitors • Examples: Acarbose (Precose), Miglitol (Glyset) • Mechanism: acts at the brush border in the small intestine to delay glucose absorption • SA’s: flatulence, abdominal pain, diarrhea • Cost: $80-$90/month • Note: Shown to decrease CV events

  28. Amylin Analogues • Examples: Pramlintide (Symlin) • Mechanism: exact mechanism of action unknown; decreases postprandial plasma glucose rise, suppresses glucagon secretion, slows gastric emptying • SA’s: nausea, vomiting, anorexia, headache, diarrhea • Caution: Severe hypoglycemia can occur, especially with co-administration of insulin • Cost: $150-$250/month

  29. Incretin Enhancers • Examples: Januvia, Onglyza • Mechanism: slows incretin metabolism, increasing insulin synthesis/release, decreasing glucagon levels • SA’s: nausea & vomiting • Caution: adjust dosage in pts with RI • Cost: $180/month

  30. IncretinMimetics • Examples: Byetta • Mechanism: enhances insulin secretion in response to elevated plasma glucose levels • SA’s: nausea & vomiting, diarrhea, dizziness • Caution: not recommended in pts with Cr Cl < 30 • Cost: $250/month • Tidbit: derived from a compound found in the saliva of the Gila monster, a large lizard native to the southwestern US

  31. Thiazolidinediones (TZDs) • Examples: Actos & Avandia • Mechanism: increases insulin sensitivity in peripheral tissue, and to a lesser extent, decreases hepatic glucose production • SA’s: wt gain, fluid retention • Caution: liver dz, pregnancy, HF, association between Avandia and CV events • Cost: $150/month

  32. Goal for Blood Glucose • Maintain as close to normal as possible without causing hypoglycemia • ADA recommends A1C < 7% • In relatively well-controlled DM, home monitoring has not been associated with significant improvement in A1C levels

  33. Rapid Acting Insulin • Lispro (Humalog), Aspart (Novolog) onset: 5-15 minutes peak: 1-2 hours duration: 4-5 hours • Regular (Humulin R) onset: 30-60 minutes peak : 2-4 hours duration: 8-10 hours note: inject 30 minutes before meal

  34. Intermediate-Acting Insulin • NPH (Humulin N) onset: 1-2 hours peak: 4-8 hours duration: 10-20 hours

  35. Long-Acting Insulin • Glargine (Lantus) onset: 1-2 hours peak: relatively flat duration: 20-24 hours dosing: start at 10 units per day, titrate at 2 units per day q 3 days

  36. References • Boyd A, Benjamin H, Chad A. Principles of Casting and Splinting. American Family Physician. Jan 1, 2009. • Ripsin C, Randall U. Management of Blood Glucose in Type 2 Diabetes Mellitus. American Family Physician. Jan 1, 2009.

More Related